This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Chronic GVHD of Liver or Lungs by ECP

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2005 by Medical University of Vienna.
Recruitment status was:  Recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: January 3, 2006
Last updated: NA
Last verified: December 2005
History: No changes posted
Chronic graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation and the leading cause of death more than 2 years after transplantation.During the past 30 years survival of patients with chronic GVHD has not improved and steroids remained the most often used therapy. Extracorporeal photoimmunotherapy (ECP)has shown to be efficacious in patients with GVHD. We propose a phase II study to evaluate the safety and efficacy of ECP as adjunct first-line therapy in patients with newly diagnosed chronic GVHD of liver or lungs and need for systemic immunosuppression defined according to the NIH consensus criteria.

Condition Intervention Phase
Chronic Graft-Versus Host Disease Procedure: Extracorporeal photoimmunotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study for Treatment of Chronic Graft-Versus-Host Disease of the Liver or Lungs With Adjunct Extracorporeal Photoimmunotherapy

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • GVHD response of the liver or lungs

Secondary Outcome Measures:
  • transplant-related mortality
  • relapse-free survival
  • overall survival
  • time to complete resolution of chronic GVHD to first-line immunosuppressive therapy
  • time to discontinuation of immunosuppressive therapy
  • duration of response to first-line immunosuppressive therapy
  • percentage of patients in need of secondary treatment for chronic GVHD
  • incidence of bacterial, viral and fungal infections
  • side effects of ECP

Estimated Enrollment: 20
Study Start Date: December 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence of at least one diagnostic clinical sign of chronic GVHD or an appropriate constellation of distinctive signs confirmed by biopsy or other relevant diagnostic tests
  • Presence of liver or lung manifestations of chronic GVHD
  • Indication for systemic immunosuppressive therapy defined according to NIH consensus
  • No prior immunosuppressive therapy for chronic GVHD of the liver or lungs
  • Adequate renal, hepatic, pulmonary and cardiac function
  • Karnofsky performance score >- 50%
  • Women of childbearing potential must agree to use a reliable method of birth control for the duration of the study
  • Signed written informed consent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00271869

Contact: Hildegard T Greinix, MD 43-1-40400 ext 4457
Contact: Christoph Zielinski, MD 43-1-40400 ext 4457

Medical University of Vienna, Department of Medicine I, BMT Recruiting
Vienna, Austria, A-1090
Contact: Hildegard T Greinix, Professor of Medicine    43-1-40400 ext 4457   
Principal Investigator: Hildegard T Greinix, Professor of Medicine         
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Hildegard T Greinix, Professor of Medicine Medical University of Vienna
  More Information Identifier: NCT00271869     History of Changes
Other Study ID Numbers: EK Nr. 368/2005
Study First Received: January 3, 2006
Last Updated: January 3, 2006

Keywords provided by Medical University of Vienna:
hematopoietic stem cell transplantation
graft-versus-host disease

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases processed this record on June 23, 2017